TrialCancer2010

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Giuseppe Saglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.